Original Investigation

Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center

10.5152/jtgga.2016.15208

  • Duygu Kavak Cömert
  • Işın Üreyen
  • Alper Karalok
  • Tolga Taşçı
  • Osman Türkmen
  • Reyhan Öcalan
  • Taner Turan
  • Gökhan Tulunay

Received Date: 02.03.2016 Accepted Date: 13.04.2016 J Turk Ger Gynecol Assoc 2016;17(2):96-100 PMID: 27403076

Objective:

To analyze the clinicopathologic features, recurrence and survival rates, reproductive history, and treatment of patients with mucinous borderline ovarian tumors (mBOTs).

Material and Methods:

Patients with a diagnosis of mBOT were evaluated retrospectively. Patients with borderline ovarian tumors other than mucinous type and concomitant invasive cancer were excluded.

Results:

A total of 75 patients were identified. Median age was 38 years. The most common symptom was pain (42.7%). Median CA-125 level was 23.5 IU/mL (range, 1–809 IU/mL). Median tumor size was 200 mm (range, 40-400 mm), and 6.7% of mBOTs were bilateral. Thirty-six (48%) patients underwent staging surgery. Two patients (5.9%) had nodal involvement. One patient received platinum-based adjuvant chemotherapy. One (1.3%) patient had recurrence. None of the patients died because of the ovarian tumor. A total of 43 patients had conservative surgery.

Conclusion:

Prognosis of mBOTs is excellent, and fertility-sparing surgery should be considered in the reproductive age group. Furthermore, the necessity of staging surgery is controversial.

Keywords: Borderline ovarian tumor, mucinous, surgical approaches